Litmus email source
Copy source
<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office"> <head> <title>Novo Nordisk</title> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> <o:PixelsPerInch>96</o:PixelsPerInch> </o:OfficeDocumentSettings> </xml><![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table { border-collapse: collapse; border-spacing: 0; mso-line-height-rule: exactly; mso-margin-bottom-alt: 0; mso-margin-top-alt: 0; mso-table-lspace: 0pt; mso-table-rspace: 0pt;} td {mso-hyphenate: none;} </style> <![endif]--> <!--[if gte mso 9]> <style> sup, sub { font-size: 100% !important; } </style> <![endif]--> <style type="text/css"> @media screen { @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 400; font-display: fallback; src: local('Noto Sans Italic'), local('NotoSans-Italic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0OIpQlx3QUlC5A4PNr4ARCQ_mu72Bi.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold Italic'), local('NotoSans-BoldItalic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0TIpQlx3QUlC5A4PNr4Az5ZuyDzW1IPrie.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 400; font-display: fallback; src: local('Noto Sans'), local('NotoSans'), url('https://fonts.gstatic.com/s/notosans/v9/o-0IIpQlx3QUlC5A4PNr5TRASf6M7Q.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold'), local('NotoSans-Bold'), url('https://fonts.gstatic.com/s/notosans/v9/o-0NIpQlx3QUlC5A4PNjXhFVZNyBx2pqPA.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } } #outlook a { padding: 0; } .ReadMsgBody { width: 100%; } .ExternalClass { width: 100%; } .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div { line-height: 100%; } body, table, td, a { -webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%; } table, td { mso-table-lspace: 0pt; mso-table-rspace: 0pt; } img { -ms-interpolation-mode: bicubic; } body { margin: 0; padding: 0; } img { border: 0; height: auto; line-height: 100%; outline: none; text-decoration: none; } table { border-collapse: collapse !important; } body { height: 100% !important; margin: 0 auto !important; padding: 0; width: 100% !important; } .grey-text a { color: #4a4a4a; text-decoration: none; } .default-blue-link-text a { color: #025edc; text-decoration: underline; } .pricing-block-text a { color: #025edc; text-decoration: underline; } .pricing-block-text sup { font-size: 70%; line-height: 0; } @media screen and (max-width: 670px) { img.img-max { max-width: 100% !important; height: auto !important; } } @media screen and (max-width: 670px) { img.img-responsive { width: 100% !important; height: auto !important; } } @media screen and (max-width: 670px) { table.mobile-hide, td.mobile-hide, img.mobile-hide, .mobile-hide { display: none !important; } } @media screen and (max-width: 670px) { div.mobile-only-content { display: block !important; max-height: none !important; max-width: 100% !important; height: auto !important; width: auto !important; visibility: visible !important; } } @media screen and (max-width: 670px) { td.responsive-td { display: block !important; width: 100% !important; } } @media screen and (max-width: 670px) { .email-container { max-width: 610px !important; width: 100% !important; } } @media screen and (max-width: 670px) { .col-80 { width: 100% !important; } .col-280 { width: 100% !important; } } @media screen and (max-width: 670px) { .mfs-10 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 10px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .mfs-11 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 11px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .mfs-12 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 12px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .mfs-14 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 14px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .mfs-18 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 18px !important; line-height: 1.3; } } @media screen and (max-width: 670px) { .mfs-20 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 20px !important; line-height: 1.3; } } @media screen and (max-width: 670px) { .mfs-28 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 28px !important; line-height: 1.2; } } @media screen and (max-width: 670px) { .mlh-14 { line-height: 14px !important; } } @media screen and (max-width: 670px) { .mlh-18 { line-height: 18px !important; } } @media screen and (max-width: 670px) { .mlh-20 { line-height: 20px !important; } } @media screen and (max-width: 670px) { .mlh-24 { line-height: 24px !important; } } @media screen and (max-width: 670px) { .mlh-25 { line-height: 25px !important; } } @media screen and (max-width: 670px) { .mlh-34 { line-height: 34px !important; } } @media screen and (max-width: 670px) { .text-center { text-align: center !important; } } @media screen and (max-width: 670px) { .mpt-0 { padding-top: 0px !important; } .mpb-4 { padding-bottom: 4px !important; } .mpt-8 { padding-top: 8px !important; } .mpb-8 { padding-bottom: 8px !important; } .mpt-10 { padding-top: 10px !important; } .mpb-16 { padding-bottom: 16px !important; } .mpt-28 { padding-top: 28px !important; } .mpb-30 { padding-bottom: 30px !important; } .mpt-36 { padding-top: 36px !important; } .mpb-40 { padding-bottom: 40px !important; } } @media screen and (max-width: 670px) { .email-gutter { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only-15 { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only-50 { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only-55 { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-only { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-10 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-15 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-30 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-50 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-80 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-90 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-100 { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-10 { padding-right: 10px !important; padding-left: 10px !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-20 { padding-right: 20px !important; padding-left: 20px !important; } } </style> </head> <body style="background-color: #ffffff;"> <center style="width: 100%"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color: #ffffff;"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-desktop-only" style="padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="border-bottom: 1px solid #E5E3E6;"> <tr> <td valign="top" class="email-gutter-15" style="padding-bottom: 10px; padding-left: 15px; padding-right: 15px; padding-top: 10px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 1.4;">$PRE_HEADER$</td> <td align="right" valign="top" style="color: #4a4a4a; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 1.4; width: 100px;"> <a href="#" target="_blank" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">View online</a> </td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="center" class="email-gutter-desktop-only" style="padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top" class="email-gutter-mobile-10"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" class="mpt-8" style="padding-bottom: 8px; padding-top: 12px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <th align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 4px; padding-top: 4px;"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307#isi" target="_blank" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Important Safety Information</a> </th> <th align="center" style="color: #4a4a4a; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 4px; padding-top: 4px;"> | </th> <th align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 4px; padding-top: 4px;"> <a href="https://www.novo-pi.com/alhemo.pdf?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Prescribing Information</a> </th> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-90" style="padding-bottom: 20px; padding-left: 90px; padding-right: 90px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="mpb-4 email-gutter-mobile-only" style="padding-bottom: 8px; padding-left: 0; padding-right: 0;"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/alhemo-logo.png" width="160" height="90" alt="Alhemo® logo" style="display: inline-block;"> </a> </td> </tr> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 13px; font-style: italic; font-weight: normal; line-height: 18px; padding-bottom: 10px;"> Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with or without Factor VIII or IX inhibitors. </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" style="background-color:#7A4BFF;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: bold; line-height: 1.4; padding-bottom: 7px; padding-top: 7px;"> <a href="https://www.novomedlink.com/account/create.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Sign up</a> to stay in the know </td> </tr> </table> </td> </tr> <tr> <td align="center" style="background-color:#280E73;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="email-gutter-50" style="padding-bottom: 10px; padding-left: 50px; padding-right: 50px; padding-top: 50px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" class="mfs-28 mlh-34" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 46px; font-weight: bold; line-height: 52px; padding-bottom: 20px;"> Demonstrated efficacy in hemophilia B and A </td> </tr> <tr> <td align="left" class="mfs-18 mlh-24" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 30px; font-weight: normal; line-height: 1.2; padding-bottom: 20px;"> Powerful everyday bleed protection for patients with hemophilia B or A<sup style="font-size: 60%; line-height: 1;">1,2</sup> </td> </tr> <tr> <td align="center" class="mfs-12 mlh-18 email-gutter-desktop-only-50" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 26px; padding-left: 50px; padding-right: 50px;"> Adherence to daily dosing of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is important to maintain protection against bleeding. </td> </tr> <tr> <td align="center" class="email-gutter-desktop-only-15" style="padding-left: 15px; padding-right: 15px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="mfs-10 mlh-14 email-gutter-10" style="background: #4FCFFB; border-radius: 10px; color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 10px; padding-left: 10px; padding-right: 10px; padding-top: 10px;"> Primary Endpoint: The estimated mean ABR ratio in patients with hemophilia B was 0.21 (<em>P</em><0.001) </td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="center" style="padding-bottom: 16px; padding-top: 5px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/efficacy-chart-desktop.png" width="558" height="521" alt="Estimated mean ABR reduction chart" class="img-responsive" style="display: block;"> </td> </tr> <tr> <td align="left" class="email-gutter-100 mfs-14 mlh-20" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: normal; line-height: 1.3; padding-bottom: 24px; padding-left: 100px; padding-right: 100px; padding-top: 20px;"> In patients with Hemophilia B, Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> for prophylaxis reduced treated spontaneous and traumatic bleeds by <strong style="color:#4FCFFB;">79% vs. on-demand FIX treatment.</strong> </td> </tr> <tr> <td align="left" class="email-gutter-100 mfs-10 mlh-14" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: 100; line-height: 1.4; padding-bottom: 24px; padding-left: 100px; padding-right: 100px;"> Study design: explorer8 was a phase 3, open-label study evaluating Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> for routine PPx in 118 adult (67 HA and 51 HB) and 38 adolescent (23 HA and 15 HB) males. Efficacy was evaluated separately in HA and HB when patients previously treated on demand in arms 1 (no PPx; on-demand factor replacement) and 2 (Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> PPx) had completed the main part of the trial (at least 24 or at least 32 weeks, respectively), based on the number of treated bleeding episodes, comparing Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> PPx with on-demand factor. Ratio of the ABR was estimated using a negative binomial model.<sup style="font-size: 70%; line-height: 1;">1</sup> </td> </tr> <tr> <td align="left" class="email-gutter-100 mfs-10 mlh-14" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 24px; padding-left: 100px; padding-right: 100px;"> In HA, using a negative binomial model, a ratio of the ABR was estimated to 0.14 (P<0.001), corresponding to a reduction in ABR of 86% for patients on Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> PPx compared with on-demand FVIII. The mean ABR was 2.7 [95% CI: 1.63; 4.59] for patients on Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> PPx (arm 2) and 19.3 [95% CI: 11.25; 33.03] for patients on on-demand FVIII (arm 1).<sup style="font-size: 70%; line-height: 1;">1</sup> </td> </tr> <tr> <td align="center" style="padding-bottom: 24px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/pen-inline.png" width="526" height="82" alt="Alhemo® prefilled pen" class="img-max" style="display: block;"> </td> </tr> <tr> <td align="left" class="mfs-14 mlh-20 email-gutter-90" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 1.4; padding-bottom: 36px; padding-left: 90px; padding-right: 90px;"> Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is delivered via a prefilled, subcutaneous pen—designed to transform how patients administer treatment.<sup style="font-size: 70%; line-height: 1;">1,a,b</sup> </td> </tr> <tr> <td align="center" style="padding-bottom: 26px;"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo/efficacy-safety/prophylaxis.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="background-color: #fbb03b; border-radius: 40px; color: #001965; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 16px; mso-padding-alt: 0; padding-bottom: 16px; padding-left: 36px; padding-right: 36px; padding-top: 16px; text-decoration: none; text-underline-color: #fbb03b;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Explore efficacy<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> <tr> <td align="left" class="email-gutter-30" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 10px; font-weight: normal; line-height: 1.4; padding-bottom: 60px; padding-left: 30px; padding-right: 30px;"> <sup style="font-size: 70%; line-height: 1;">a</sup>Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is intended for use under the guidance of a healthcare provider and may be self-administered or administered by a caregiver after appropriate training and reading the <a href="https://www.novo-pi.com/alhemo.pdf?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Instructions for Use</a> if a healthcare provider determines that is appropriate.<br> <sup style="font-size: 70%; line-height: 1;">b</sup>Needles sold separately and may require a prescription in some states. New needle is required for each injection. </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" height="20" style="height:20px;line-height:20px;background-color:#ffffff"> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-mobile-only" bgcolor="#E3DBFC" style="background: #E3DBFC; padding-bottom: 16px; padding-left: 0; padding-right: 0; padding-top: 24px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" class="mfs-20 mlh-25 mpb-8" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 34px; font-weight: bold; line-height: 38px; padding-bottom: 12px; padding-top: 16px;"> Personalized protection with an optimized/individualized dose </td> </tr> <tr> <td align="center" class="mfs-14 mlh-20 email-gutter-desktop-only-55 mpt-0" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 1.4; padding-bottom: 10px; padding-left: 55px; padding-right: 55px; padding-top: 10px;"> The Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> dosing tool makes it easy to individualize prophylaxis dosing for each patient—helping you tailor treatment to their unique needs. </td> </tr> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 1.4;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/dosing-tool-desktop.png" width="605" height="264" alt="Alhemo dosing tool illustration" class="img-responsive" style="display: block;"> </td> </tr> <tr> <td align="center" style="padding-bottom: 18px; padding-top: 10px;"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo/dosing-administration/dosing-with-the-alhemo-pen.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307#dosing-tool" target="_blank" style="background-color: #fbb03b; border-radius: 40px; color: #001965; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 16px; mso-padding-alt: 0; padding-bottom: 18px; padding-left: 24px; padding-right: 24px; padding-top: 18px; text-decoration: none; text-underline-color: #fbb03b;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Check out our dosing tool<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" height="20" style="height:20px;line-height:20px;background-color:#ffffff"> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" bgcolor="#4FCFFB" style="background-color: #4FCFFB; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 10px; padding-left: 30px; padding-right: 30px; padding-top: 16px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 1.4; padding-bottom: 4px;">Keep scrolling to learn more about Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup></td> </tr> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 1.4; padding-bottom: 5px; padding-top: 15px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/arrow.png" width="44" height="23" alt style="display: block;"> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" bgcolor="transparent" style="background: transparent; background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 26px; padding-bottom: 20px;">Important Safety Information</td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 12px;">Contraindications</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">•</td> <td width="5"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is contraindicated in patients with a history of known serious hypersensitivity to Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> or its ingredients</td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 12px;">Warnings and Precautions</td> </tr> <tr> <td align="left" style="padding-bottom: 16px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">•</td> <td width="5"> </td> <td align="left"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Thromboembolic Events (TEs):</b> Venous and arterial TEs were reported in 1.9% of patients (6/320) who also had multiple risk factors, including the use of high doses or prolonged treatment with factor product or bypassing agent (2 of 6 patients). Risk factors for TEs may also include conditions in which tissue factor is overexpressed (eg, atherosclerotic disease, crush injury, cancer, disseminated intravascular coagulation, thrombotic microangiopathy, or septicemia). Inform patients about and monitor them for signs and symptoms of TEs. In case of suspicion of TEs, discontinue Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> and initiate further investigations and management strategies</td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 16px;">Please <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/alhemo.html?showisi=true&tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or scroll below for additional Important Safety Information.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #DBF5FF; width: 670px;"> <tr> <td align="center" class="email-gutter-50 mpt-36 mpb-40" style="padding-bottom: 56px; padding-left: 50px; padding-right: 50px; padding-top: 56px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" class="responsive-td"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" class="mpt-10 text-center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: bold; line-height: 28px; padding-bottom: 30px; padding-top: 40px;">Have questions? <br>We’re here to help.</td> </tr> <tr> <td align="left" class="mpb-30"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/resources/novonordisk-representative.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="background-color: #DBF5FF; border: 2px solid #001965; border-radius: 40px; color: #001965; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 16px; mso-padding-alt: 0; padding-bottom: 10px; padding-left: 25px; padding-right: 25px; padding-top: 10px; text-decoration: none; text-underline-color: #DBF5FF;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Contact your rep<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> <td align="center" valign="top" width="280" style="width: 280px;" class="responsive-td"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" class="text-center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 20px;">Connect with a Novo Nordisk Rare Blood Therapy Manager in your area. They can help you with:</td> </tr> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="max-width: 320px;"> <tr> <td align="left" valign="top" width="30" style="padding-bottom: 10px; width: 30px;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 10px;">Clinical product information</td> </tr> <tr> <td align="left" valign="top" width="30" style="padding-bottom: 10px; width: 30px;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 10px;">Rare bleeding education for patients</td> </tr> <tr> <td align="left" valign="top" width="30" style="padding-bottom: 10px; width: 30px;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 10px;">Resources for starting treatment</td> </tr> <tr> <td align="left" valign="top" width="30" style="padding-bottom: 10px; width: 30px;"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/checkmark.png" width="20" height="20" alt style="display: block;"></td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 10px;">General questions & inquiries</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" height="20" style="height:20px;line-height:20px;background-color:#ffffff"> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #001965; width: 670px;"> <tr> <td align="center" class="email-gutter-80" style="padding-bottom: 40px; padding-left: 80px; padding-right: 80px; padding-top: 40px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="mpb-16" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: bold; line-height: 28px; padding-bottom: 28px;">Do you have a novoMEDLINK™ account?</td> </tr> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 28px;">Complete a simple registration to receive the latest product news and education from Novo Nordisk.</td> </tr> <tr> <td align="center" style="padding-bottom: 24px;"><a href="https://www.novomedlink.com/account/create.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="background-color: #ffffff; border-radius: 40px; color: #001965; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 16px; mso-padding-alt: 0; padding-bottom: 10px; padding-left: 30px; padding-right: 30px; padding-top: 10px; text-decoration: none; text-underline-color: #ffffff;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Register<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 22px; padding-bottom: 28px;">With a novoMEDLINK™ account you can:</td> </tr> <tr> <td align="center" class="email-gutter-mobile-20"> <table border="0" cellpadding="0" cellspacing="0" class="col-280" style="width: 280px;"> <tr> <td width="50" style="width: 50px;" align="left" valign="middle"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/icon-book.png" width="30" height="40" alt style="display: block;"></td> <td align="left" valign="middle" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px;">Order educational materials</td> </tr> <tr> <td width="50" height="20" style="width: 50px; height: 20px; line-height: 20px;"> </td> <td height="20" style="height: 20px; line-height: 20px;"> </td> </tr> <tr> <td width="50" style="width: 50px;" align="left" valign="middle"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/icon-list-bullets.png" width="30" height="30" alt style="display: block;"></td> <td align="left" valign="middle" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px;">Access the latest product information</td> </tr> <tr> <td width="50" height="20" style="width: 50px; height: 20px; line-height: 20px;"> </td> <td height="20" style="height: 20px; line-height: 20px;"> </td> </tr> <tr> <td width="50" style="width: 50px;" align="left" valign="middle"><img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/icon-updates.png" width="30" height="36" alt style="display: block;"></td> <td align="left" valign="middle" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px;">Receive personalized updates</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 8px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"><table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 26px; padding-bottom: 16px;">Indications and Usage for Alhemo<sup style="font-size: 60%; line-height: 1;">®</sup></td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; padding-bottom: 28px;">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with or without Factor VIII or IX inhibitors.</td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 26px; padding-bottom: 20px;">Important Safety Information (cont’d)</td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 12px;">Warnings and Precautions (cont'd)</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Hypersensitivity Reactions:</b> Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is contraindicated in patients with a history of known serious hypersensitivity to Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> or its ingredients. Hypersensitivity reactions, including erythema, rash, pruritus, and abdominal pain, have occurred in patients treated with Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup>. One patient (<1%) experienced anaphylaxis, which resolved after treatment with antihistamines and corticosteroids. Instruct patients of the signs of acute hypersensitivity reactions and to contact their healthcare provider for mild reactions and to seek urgent medical attention for moderate to severe reactions. Discontinue Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> if severe hypersensitivity symptoms occur and initiate medical management</td> </tr> </table> </td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Increased Laboratory Values of Fibrin D-dimer and Prothrombin Fragment 1.2:</b> Increased levels of fibrin D-dimer and prothrombin fragment 1.2 were seen in 29 (9.1%) and 26 (8.1%) patients, respectively, which is positively correlated with the plasma concentration of concizumab-mtci, indicating a hemostatic effect. For patients taking Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup>, these coagulation biomarkers may not be reliable predictive markers for clinical decision-making with suspicion of thrombosis, such as deep vein thrombosis and pulmonary embolism</td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 12px;">Adverse Reactions</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">The most frequently reported adverse reactions (≥5%) were injection site reactions, headache, and urticaria</td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;">Serious adverse reactions were reported in 6.1% of patients with inhibitors who received Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup>. Permanent discontinuation of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> occurred in 1 patient due to a renal infarct and dosage interruptions of Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> occurred in 1 patient (3%) and was a hypersensitivity reaction</td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #7A4BFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 12px;">Drug Interactions</td> </tr> <tr> <td align="left" style="padding-bottom: 20px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; width: 20px;">•</td> <td width="5" style="width: 5px;"> </td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"><b>Breakthrough Bleeding Treatment:</b> Take appropriate precautions when treating breakthrough bleeding events in patients receiving Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> prophylaxis and FVIII or FIX or a bypassing agent (eg, rFVIIa or aPCC). For mild and moderate bleeds, the lowest approved dose in the approved product labeling is recommended. For aPCC, a maximum dose of 100 units/kg within 24 hours is recommended. For severe bleeds, follow the dosing instructions in the approved labeling based on clinical judgment</td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 1.4; padding-bottom: 12px;">Please <a href="https://www.novo-pi.com/alhemo.pdf?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> for Prescribing Information.</td> </tr> </table> </td> </tr> </table></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="left" class="email-gutter" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 10px; padding-left: 30px; padding-right: 30px;"> <p style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: bold; line-height: 1.4;">References:</p> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" valign="top" width="10" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; width: 15px;">1.</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4;">Alhemo [Prescribing Information]. Novo Nordisk Inc.</td> </tr> <tr> <td align="center" valign="top" width="10" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; width: 15px;">2.</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4;">Chowdary P, Angchaisuksiri P, Apte S, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. <em>Lancet Haematol</em>. 2024;11(12):e891-e904.</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 24px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%" style="border-top:1px solid #979797"> <!-- Pricing Block Start --> <tr> <td align="left" class="pricing-block-text" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-style: italic; font-weight: bold; line-height: 18px; padding-top: 25px;"> Please click on the link to see WAC pricing for the product mentioned above: <a href="https://www.novopricing.com/alhemo.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;" target="_blank">Product Pricing</a>. </td> </tr> <!--Pricing Block End --> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px; padding-top: 24px;"> <span class="default-blue-link-text">Please do not respond to this email. If you would like to contact us, please <a href="https://www.novonordisk-us.com/contact-us.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or call <span class="default-blue-link-text" style="white-space: nowrap;">1-877-744-2579</span>.</span> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: bold; line-height: 16px; padding-top: 16px;">UNSUBSCRIBE NOTICE</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"> <span class="grey-text">If you no longer want to receive communications from Novo Nordisk, <a href="#" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> to unsubscribe. You also may call us at <span class="default-blue-link-text" style="white-space: nowrap;">1‑800‑727-6500</span> or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our <a href="https://www.novonordisk-us.com/privacy-notice.html?tc=em_lu3t908&cc=5003&utm_medium=email&utm_source=almk&utm_campaign=alhemo_promotional&utm_content=safety_and_efficacy_us25ahm00307" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Privacy Statement</a>.</span> </td> </tr> </table> </td> </tr> <tr> <td valign="bottom" class="mpt-28" style="padding-bottom: 20px; padding-top: 20px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="bottom" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 16px;"> <span class="grey-text">Alhemo<sup style="font-size: 70%; line-height: 1;">®</sup> is a registered trademark of Novo Nordisk Health Care AG.<br>novoMEDLINK™ is a trademark of Novo Nordisk A/S.<br>Novo Nordisk is a registered trademark of Novo Nordisk A/S.<br>© 2025 Novo Nordisk All rights reserved. <span style="white-space: nowrap;">US25AHM00307</span> <span style="white-space: nowrap;">September 2025</span></span> </td> <td align="right" valign="bottom" class="col-80 mobile-hide" style="width: 80px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"> </td> </tr> </table> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" valign="top" style="padding-top: 20px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/alhemo-hcp-hem-b-phase-2-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"> </td> </tr> </table> </div> <!--<![endif]--> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </center> </body> </html>